Threshold Pharma announces clinical development results for TH-302
Threshold Pharmaceuticals announced a presentation related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The presentation was made at the Chemotherapy Foundation Symposium taking place in New York City from November 10 to 14. :theflyonthewall.com
News For THLD From The Last 14 Days
Check below for free stories on THLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
